Royalty Pharma plc (RPRX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $54.98 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.7% away).
Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. In 2025, it generated $3.3B in Portfolio Receipts and deployed $2.6B to acquire... Read more
Sell if holding. Analyst target reached at $54.98 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.7% away). Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Royalty Pharma plc
Latest news
- NEWS Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance — Yahoo Finance positive
- NEWS Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Should You Buy? - MarketBeat — MarketBeat positive
- NEWS Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Still a Buy? - MarketBeat — MarketBeat positive
- NEWS Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings - TradingView — TradingView positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductcystic fibrosis franchise10-K Item 1: 'Cystic fibrosis franchise(2)| Vertex| Rare disease| Cystic fibrosis| $917| $11,725'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $54.98 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.7% away). Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $52.28. Score 5.3/10, moderate confidence.
Take-profit target: $55.37 (+0.7% upside). Prior stop was $52.28. Stop-loss: $52.28.
Analyst target reached - limited upside remaining; Near 52-week high (2.7% away); Negative momentum.
Royalty Pharma plc trades at a P/E of 28.9 (forward 9.8). TrendMatrix value score: 4.7/10. Verdict: Sell.
16 analysts cover RPRX with a consensus score of 4.2/5. Average price target: $59.
What does Royalty Pharma plc do?Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies...
Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. In 2025, it generated $3.3B in Portfolio Receipts and deployed $2.6B to acquire new royalties. Revenue is royalty payments tied to the top-line sales of funded therapies.